AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved by the European Commission (EC) for ...

AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for their TROP2-directed antibody-drug ...

DATROWAY® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

Datroway (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with ...

Among 35 patients who received Datroway at a lower 4 mg/kg dose, investigators recorded a 43% ORR for the combination. The two patient groups had similar follow-up times at about 13 months ...

AstraZeneca (LSE:AZN) saw its share price decline by 3.5% in the last quarter, a period marked by several key developments, including the European approval of DATROWAY for breast cancer treatment and ...

First approval in the EU for Daiichi Sankyo and AstraZeneca’s DATROWAY based on TROPION-Breast01 trial showing 37% reduction in the risk of disease progression or death versus chemotherapy ...

DATROWAY ® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative ...